USPTO 2015–2025 USPTO PatentsView US Corporation

Ariosa Diagnostics, Inc.

USPTO PatentsView assignee record - 25 granted patents across 3 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).

25
Total patents granted
3
CPC technology areas
22.0
Avg claims per patent
+8%
5-year filing velocity

The verdict

Ariosa holds 25 US patents across 3 technology areas, rank #11,926 of 50,000 tracked assignees.

#11,926
of 50,000 US assignees by volume
Top 60%
by Innovation Score (32.1/100)
22.0
avg claims per patent
+8%
filing velocity, last 5 yrs

Portfolio overview

Ariosa Diagnostics, Inc. has been granted 25 US utility patents between 2015 and 2025, placing Ariosa Diagnostics, Inc. at rank #11,926 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 22.0 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a US Corporation, Ariosa Diagnostics, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 32.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 13 grants, compared with 12 in the 2015–2019 window, a +8% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Ariosa Diagnostics, Inc.'s 22.0 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Ariosa Diagnostics, Inc. against peers pursuing similar technology classes.

How does Ariosa compare?

Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀

patents

What this shows Ariosa holds 25 patents, placing it at rank #11,926 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Ariosa's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

32 Top 60% higher than 40% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

0123456 20152017201820192020202120222025 1
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Ariosa Diagnostics, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 1 4.0%
2017 2 8.0%
2018 5 20.0%
2019 4 16.0%
2020 4 16.0%
2021 5 20.0%
2022 3 12.0%
2025 1 4.0%

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Complex
Velocity Growing

Where it ranks

Overall rank by patents

#11,926

Across all tracked assignees

Innovation Score

32.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Ariosa Diagnostics, Inc. hold?
Ariosa Diagnostics, Inc. holds 25 US granted patents filed between 2015 and 2025, spanning 3 technology areas.
What is Ariosa Diagnostics, Inc.'s Innovation Score?
Ariosa Diagnostics, Inc. has an Innovation Score of 32.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Ariosa Diagnostics, Inc. focus on?
Ariosa Diagnostics, Inc.'s top technology area is C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES) with 20 patents. The company has filed patents in 3 CPC subclasses total.
Is Ariosa Diagnostics, Inc.'s patent filing rate increasing or decreasing?
Ariosa Diagnostics, Inc.'s recent filing velocity is +8% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for Ariosa Diagnostics, Inc.'s patents?
Ariosa Diagnostics, Inc.'s patents average 22.0 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Ariosa Diagnostics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Guides to patent portfolio analysis

How to use this portfolio

Ariosa's 25 grants land it in the top 60% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Ariosa ranks #11,926 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C12Q - see who else leads that technology area. C12Q leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov